June 15, 2020 / 8:47 PM / 2 months ago

BRIEF-Celldex Plans To Initiate Phase 1B Studies Of Cdx-0159 In Patients With Chronic Spontaneous Urticaria By Year End

June 15 (Reuters) - Celldex Therapeutics Inc:

* CELLDEX - PLANS TO INITIATE PHASE 1B STUDIES OF CDX-0159 IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA, CHRONIC INDUCIBLE URTICARIA BY YEAR END

* CELLDEX THERAPEUTICS - FULL RESULTS FROM CINDU & CSU STUDIES AS CURRENTLY PLANNED WOULD BE AVAILABLE IN Q1 2021 & 2H 2021, RESPECTIVELY.

* CELLDEX - INTEND TO INITIATE PHASE 1B STUDY OF CDX-0159 IN 20 PATIENTS WITH CINDU AT URTICARIA CENTER OF EXCELLENCE IN GERMANY FROM FALL 2020

* CELLDEX - RESULTS FROM PHASE 1B STUDY OF CDX-0159 IN GERMANY EXPECTED IN Q1 2021 Source : (bit.ly/3e0uOvn) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below